Sarepta Therapeutics Inc (NASDAQ:SRPT) CEO Douglas S. Ingram bought 16,695 shares of the company’s stock in a transaction on Tuesday, October 30th. The shares were bought at an average price of $120.39 per share, for a total transaction of $2,009,911.05. Following the transaction, the chief executive officer now owns 412,811 shares of the company’s stock, valued at $49,698,316.29. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of SRPT stock opened at $141.99 on Friday. The company has a current ratio of 10.88, a quick ratio of 9.89 and a debt-to-equity ratio of 0.62. Sarepta Therapeutics Inc has a 52-week low of $48.77 and a 52-week high of $176.50. The firm has a market capitalization of $8.27 billion, a P/E ratio of -86.58 and a beta of 1.16.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, October 24th. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative return on equity of 22.76% and a negative net margin of 89.46%. The business had revenue of $78.49 million during the quarter, compared to analysts’ expectations of $78.84 million. On average, analysts predict that Sarepta Therapeutics Inc will post -4.38 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Comerica Bank raised its position in Sarepta Therapeutics by 20.7% during the third quarter. Comerica Bank now owns 19,760 shares of the biotechnology company’s stock valued at $2,654,000 after purchasing an additional 3,386 shares in the last quarter. Chicago Equity Partners LLC raised its position in Sarepta Therapeutics by 39.8% during the third quarter. Chicago Equity Partners LLC now owns 24,230 shares of the biotechnology company’s stock valued at $3,913,000 after purchasing an additional 6,895 shares in the last quarter. GWM Advisors LLC purchased a new stake in Sarepta Therapeutics during the third quarter valued at about $221,000. Columbus Circle Investors raised its position in Sarepta Therapeutics by 164.3% during the third quarter. Columbus Circle Investors now owns 70,761 shares of the biotechnology company’s stock valued at $11,429,000 after purchasing an additional 43,989 shares in the last quarter. Finally, Creative Planning raised its position in Sarepta Therapeutics by 11.6% during the third quarter. Creative Planning now owns 79,427 shares of the biotechnology company’s stock valued at $12,828,000 after purchasing an additional 8,280 shares in the last quarter. Institutional investors and hedge funds own 89.57% of the company’s stock.
Several research firms have issued reports on SRPT. BidaskClub downgraded Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. HC Wainwright restated a “buy” rating and set a $267.00 target price on shares of Sarepta Therapeutics in a research report on Friday, September 21st. Cantor Fitzgerald began coverage on Sarepta Therapeutics in a research report on Monday, October 1st. They set an “overweight” rating and a $217.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $200.00 target price (up previously from $187.00) on shares of Sarepta Therapeutics in a research report on Wednesday, September 26th. Finally, BTIG Research set a $190.00 target price on Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Monday, September 24th. Three equities research analysts have rated the stock with a hold rating, twenty-four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $168.37.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.
Recommended Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.